SSY Group gets China approval for overactive bladder drug

SSY Group Limited has received approval from the National Medical Products Administration of China for the drug production and registration of Tolterodine Tartrate Sustained-release Capsules (4mg). This approval signifies a key development for the group, marking it as a type 4 chemical drug that has successfully passed consistency evaluation.

The Tolterodine Tartrate Sustained-release Capsule is primarily indicated for the treatment of overactive bladder. This latest approval is the third such regulatory clearance for the PRC entities of SSY Group, underscoring the company's progress in its product development pipeline.

This voluntary announcement aims to keep shareholders and potential investors informed of the group’s latest business advancements.